Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

RESOLVE Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across Europe (RESOLVE)

Coordinator
Martin-Luther-Universitat Halle-Wittenberg, Germany
Runs
1 April 2024 to 31 March 2029
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
23 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101136502

What the project is doing

In the project's own words, from its summary on CORDIS.

Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) has strong prognostic value in patients with the most frequent acute and chronic leukemias, acute myeloid (AML) and chronic lymphocytic leukemia (CLL), but it has not yet been confirmed as a treatment-guiding biomarker. The RESOLVE Consortium will leverage numerous existing expert networks and patient advocacy partnerships to establish the predictive value of MRD in AML/CLL patients, with the expectation that this affordable, minimally-invasive biomarker can be imminently used to guide the intensity of consolidation therapy, improve quality of life (QoL), and reduce costs.

This will be achieved through 1) development of a real-world patient registry and data platform

Topics

Who is involved

OrganisationCityCountryRole
Martin-Luther-Universitat Halle-WittenbergHalleGermanyCoordinator
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyParticipant
European Research Initiative on Cll eVKolnGermanyParticipant
Medizinische Hochschule HannoverHannoverGermanyParticipant
Osho, Ostdeutsche Studiengruppe Hamatologie Und Onkologie E.v.LeipzigGermanyParticipant
Stiftung Eln FoundationWeinheimGermanyParticipant
Technische Universitaet DresdenDresdenGermanyParticipant
Universitaet UlmUlmGermanyParticipant
Elliniki Aimatologiki EtaireiaAthensGreeceParticipant
Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y LeonSoriaSpainParticipant
French Innovative Leukemia OrganizationToursFranceParticipant
Shaare Zedek Medical CenterJerusalemIsraelParticipant
Azienda Usl Della RomagnaRavennaItalyThird party
Fondazione G.i.m.em.a. - Franco Mandelli OnlusRomaItalyParticipant
Istituto Di Ricerche Farmacologiche Mario NegriMilanoItalyParticipant
Istituto Romagnolo per Lo Studio Dei Tumori Dino Amadori - Irst SRLMeldolaItalyParticipant
Universita Commerciale Luigi BocconiMilanoItalyParticipant
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
Flowview Diagnostics BVHeerenveenNetherlandsParticipant
Ortec Optimization Technology BVZoetermeerNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stowarzyszenie Polskiej Grupy D/s Leczenia Bialaczek U Doroslych Palg/polish Adult Leukemia GroupGliwicePolandParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI